<DOC>
	<DOCNO>NCT00052910</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy surgery may kill remain tumor cell follow surgery . It yet know chemotherapy radiation therapy regimen effective treat stomach esophageal cancer . PURPOSE : Randomized phase III trial compare two different chemotherapy radiation therapy regimens treat patient undergone surgery stomach esophageal cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy After Surgery Treating Patients With Stomach Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival patient resect gastric adenocarcinoma treat epirubicin , cisplatin , infusional fluorouracil ( 5-FU ) v 5-FU bolus leucovorin calcium 5-FU plus radiotherapy . - Compare disease-free survival local distant recurrence rate patient treat regimen . - Correlate expression putative prognostic marker ( include TS , ERCC-1 , MSI , E-cadherin , EGFR , p27 , COX-2 , c-erbB-2 ) overall survival patient treat regimen . - Correlate specific germline polymorphism relate chemotherapy metabolism resistance ( include UGT2B7 [ epirubicin ] , GST [ cisplatin ] , ERCCI [ cisplatin ] , XRCC1 [ cisplatin ] , TS [ 5-FU ] , DPD [ 5-FU ] , EGFR polymorphism ) treatment-related toxicity overall survival patient . - Correlate serum level insulin-like growth factor-1 ( IGF-1 ) , IGF-2 , IGF-binding protein 3 overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord depth tumor penetration ( T1 T2 v T3 v T4 ) , lymph node involvement ( 0 vs 1-3 ) , extent lymphadenectomy ( D1 D2 v D0 unknown ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive leucovorin calcium IV fluorouracil ( 5-FU ) IV day 1-5 course 1 , 3 , 4 . Courses repeat every 28 day . During course 2 , patient undergo radiotherapy 5 day week receive 5-FU IV continuously 5 week . Patients rest 28-35 day course 2 3 . - Arm II : Patients receive epirubicin IV 3-15 minute cisplatin IV 1 hour day 1 5-FU IV continuously day 1-21 course 1 . Beginning 1 week later , patient undergo radiotherapy 5 day week receive 5-FU IV continuously 5 week . Patients rest 28-35 day begin course 2 chemotherapy . Patients receive epirubicin , cisplatin , 5-FU course 1 . Treatment repeat every 21 day 2 course . Patients follow every 3 month 2 year , every 4 month 2 year , annually 3 year . PROJECTED ACCRUAL : A total 824 patient accrue study .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>1 . Required Tumor Parameters 1.1 Patients must histologically diagnose adenocarcinoma stomach gastroesophageal junction . Adenocarcinomas esophagus involve gastroesophageal junction eligible . 1.2 Patients must en bloc resection know tumor . The surgical resection must do curative intent . 1.3 Patients must tumor extension beyond muscularis propria and/or nodal involvement without evidence M1 disease . Patients stag IB evidence either nodepositive ( N1 ) disease tumor extension beyond muscularis propria ( i.e. , T1 , N1 , M0 patient eligible patient T2 , N0 , M0 allow extension beyond muscularis propria ) . Patients stag II , IIIA , IIIB stage IV M0 ( i.e. , T4N2M0 ) . Stages 0 , IA , stage M1 allow . ( see Appendix I TNM stag guide ) . 1.4 Patients know unresected cancer , recurrent cancer , microscopic evidence tumor distal proximal line stomach resection , noncontiguous resection tumor , M1 ( metastatic ) disease ineligible . 2 . Prior Therapy 2.1 No prior therapy ( except hormonal biologic ) malignancy allow except adequately treat basal cell squamous cell skin cancer , noninvasive carcinoma situ fully resect , cancer patient disease free five year . 2.2 Patients previous chemotherapy radiotherapy ineligible . 3 . Patient Characteristics 3.1 Patients must ECOG ( CTC ) performance status 0 , 1 2 . 3.2 Patients require adequate total caloric intake allow maintain postsurgical body weight . Patients must documentation stable weight ( le 2 pound weight loss ) least one week prior registration . 3.3 All patient must evaluate radiation oncologist ( prior enrollment ) ensure patient appropriate candidate radiation therapy . 3.4 Patients may unilateral renal function ( one function kidney ) determine CT scan contrast , urogram , renal scan , study . 3.5 Pregnant lactate woman may participate . Men woman reproductive potential may participate unless agree use effective contraceptive method practice abstinence study . The effect therapeutic radiotherapy know teratogenic . The effect Epirubicin , Cisplatin , 5FU develop human fetus recommend therapeutic dose less well know . For reason DNA alkylating agent know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Because risk toxicity nursing infant secondary Epirubicin , Cisplatin , 5FU treatment mother unknown may harmful , breastfeed discontinue . 3.6 Patients follow cardiac condition ineligible : Uncontrolled high blood pressure Unstable angina Symptomatic congestive heart failure Myocardial infarction &lt; 6 month prior registration Serious uncontrolled cardiac arrhythmia New York Heart Association classification III IV . 3.7 No uncontrolled serious medical psychiatric illness would prevent compliance treatment adequate inform consent . 3.8 Patients active infectious process ineligible . 3.9 Patients grade 2 great peripheral neuropathy baseline ineligible . 4 . Required Initial Laboratory Values : Granulocytes ≥ 1,500/μl Platelet count ≥ 100,000/μl Creatinine ≤ 1.5 mg/dl Bilirubin ≤ 2.0 mg/dl AST ≤ 3x upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
</DOC>